On Wednesday, Following U.S. Stocks were among the “Top Gainers”: Solazyme, (NASDAQ:SZYM), Conns, (NASDAQ:CONN), Ampio Pharmaceuticals, (NYSEMKT:AMPE), Global Cash Access Holdings, (NYSE:GCA)
Solazyme, Inc. (NASDAQ:SZYM), with shares inclined 15.27%, closed at $3.17.
Conns Inc. (NASDAQ:CONN), with shares jumped 14.63%, settled at $27.50.
Ampio Pharmaceuticals, Inc. (NYSEMKT:AMPE), with shares climbed 12.31%, and closed at $6.57.
Global Cash Access Holdings, Inc. (NYSE:GCA), surged 12.24%, and closed at $8.16.
Latest NEWS regarding these Stocks are depicted underneath:
Solazyme, Inc. (NASDAQ:SZYM)
Solazyme, Inc. (SZYM), a renewable oil and bioproducts corporation, declared recently results for the fourth quarter and full year ended December 31, 2014.
Financial Results:
Total proceed for the fourth quarter of 2014 was $14.5 million contrast with $11.3 million in the fourth quarter of 2013, an raise of 29%. Fourth quarter GAAP net loss was $44.9 million contrast to a net loss of $33.3 million in the preceding year period. On a non-GAAP basis, the net loss was $35.5 million for the fourth quarter of 2014 contrast to a net loss of $27.4 million in the preceding year quarter.
Total proceed for the year ended December 31, 2014 was $60.4 million contrast with $39.8 million in the preceding year, an raise of 52%, with the product proceed component of that up 87% as compared to the preceding year. Full year 2014 GAAP net loss was $162.1 million, contrast with $116.4 million loss in the preceding year. On a non-GAAP basis, the net loss was $133.4 million for 2014, contrast with $88.6 million in 2013.
“Solazyme’s 2014 proceed growth reflects the continued expansion of our Algenist® product line, shipments from Clinton/Galva and Peoria of Encapso™ and AlgaVia™ branded products, in addition to delivery against all of our joint development milestones for our partners,” said Tyler Painter, COO and CFO of Solazyme. “We are focused on maximizing the returns on our capacity investments and driving efficiencies across our operations. We are well positioned financially to accelerate the commercialization of our products in 2015.”
Solazyme, Inc. manufactures and sells renewable oils and other bioproducts. Its proprietary technology transforms a range of plant-based sugars into triglyceride oils and other bioproducts.
Conns Inc. (NASDAQ:CONN)
Conns Inc. (CONN), a specialty retailer of home appliances, furniture, mattresses, consumer electronics and provider of consumer credit, declared it will host a conference call on March 31, 2015 to talk about its fourth-quarter and full year fiscal 2015 financial results. The conference call will start at 10:00 A.M. CT (11:00 A.M. ET). A press release regarding the operating results will be released the same day before the market opens.
Conn’s, Inc. operates as a specialty retailer of durable consumer goods and related services in Texas, Arizona, Louisiana, Oklahoma, and New Mexico, the United States. Conn’s is presently operating about 90 retail locations in Arizona, Colorado, Louisiana, Mississippi, Nevada, New Mexico, North Carolina, Oklahoma, South Carolina, Tennessee and Texas.
Ampio Pharmaceuticals, Inc. (NYSEMKT:AMPE)
Formerly on February 25, Ampio Pharmaceuticals, Inc. (AMPE), declared results of the double-blind, multiple injection, vehicle controlled STRUT study (N=40) at 20 weeks.
The forty patient randomized (1:1) phase of the STRUT study was conducted to assure that multiple injections of Ampion™ were safe and effective. Each patient received three 4 mL intra-articular injections of Ampion™ or saline at baseline, 2 weeks and 4 weeks. There were no drug related serious adverse events stated during the 20 weeks of this trial; the top-line results are as follows:
WOMAC A: The primary endpoint that is required for FDA approval, WOMAC A pain score, improved by 64% from baseline to 20 weeks. Ampion™ improved by -1.41 (0.81) contrast to saline vehicle control which improved by -0.85 (0.64), p=0.0231.
Responder Rate: Responder rate is defined as a change of at least 1 point in the WOMAC A pain subscale. Responder rate for Ampion™ was 79% contrast to 47% of saline patients,p=0.0451.
Ampio Pharmaceuticals, Inc., a development stage biopharmaceutical corporation, develops therapies for the treatment of prevalent inflammatory conditions in the United States. The company is developing compounds that decrease inflammation by (i) inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; (ii) activating specific phosphatase or depletion of the accessible phosphate needed for the inflammation process; and (iii) decreasing vascular permeability.
Global Cash Access Holdings, Inc. (NYSE:GCA)
Global Cash Access Holdings, Inc. (GCA), stated financial results for the fourth quarter and full year ended December 31, 2014. On December 19, 2014, GCA accomplished the attainment of Multimedia Games Holding Corporation, Inc., creating a diversified organization dedicated to providing integrated payments solutions, video and mechanical reel gaming content and technology solutions, in addition to compliance and efficiency software. Unless otherwise noted, all results for the 2014 fourth quarter and full year referenced below comprise 13 days of operations from Multimedia Games.
Fourth Quarter 2014 Results Overview:
Proceeds raised $11.6 million, or 8% contrast to the same period last year, to $152.1 million in the fourth quarter of 2014. Fourth quarter 2014 proceed comprises $7.4 million from Multimedia Games and a $4.2 million, or 3%, raise in legacy GCA proceed. Operating revenue, inclusive of a $9.7 million influence for attainment costs, $0.3 million for purchase accounting adjustments, and an asset impairment charge of $3.1 million, was $0.4 million in the 2014 fourth quarter contrast to operating revenue of $11.2 million for the 2013 fourth quarter. Adjusted EBITDA raised $6.9 million, or 40%, to $24.0 million for the fourth quarter of 2014, contrast to Adjusted EBITDA of $17.1 million in the same period last year. The raise in Adjusted EBITDA comprises $4.0 million from Multimedia Games.
GCA recorded a loss from operations before revenue tax provision of $7.5 million contrast to revenue from operations before revenue tax provision of $9.1 million in the fourth quarter of 2013. Diluted loss per share from ongoing operations was $0.09 contrast to diluted earnings per share of $0.08 for the 2013 fourth quarter. Cash EPS raised to $0.23 for the fourth quarter of 2014 from Cash EPS of $0.19 in the preceding-year period. Not including the operations of Multimedia Games, Cash EPS was $0.24 for the quarter.
Randy Taylor, Executive Vice President and Chief Financial Officer, commented, “Since concluding our attainment of Multimedia Games less than three months ago, we have been focused on our integration initiatives. As of December 31, 2014, we have eliminated about $10.9 million on an annual run rate basis from our overall cost structure and we expect to achieve our targeted annual run rate of $24 million in cost synergies by calendar year end. As part of our integration plans, later this year we intend to consolidate all of our manufacturing operations which will significantly enhance manufacturing efficiencies and reduce costs. Looking forward, our plan continues to focus on the deployment of cash to reduce leverage.”
Global Cash Access Holdings, Inc. provides cash access services and related equipment and services to the gaming industry. The corporation operates in Cash Advance, ATM, Check Services, and Other segments.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
